Singh Danish, Nguyen Tivoli, Burnam Patrick, Greenberg Jacob, Raheem Omer, Hellstrom Wayne
Department of Urology, Tulane University School of Medicine, New Orleans, LA, #8642, 1430 Tulane Avenue70112, USA.
Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA, USA.
Curr Urol Rep. 2025 Jun 9;26(1):49. doi: 10.1007/s11934-025-01279-z.
The aim of this review is to evaluate recent literature surrounding the impact of new medical and surgical therapies for benign prostatic hyperplasia (BPH) on sexual health and function.
Recent randomized controlled trials evaluating patients treated with Optilume, Rezum, Urolift, iTind, and prostatic artery embolism reported minimal associated risks for the development of sexual dysfunction. However, these treatments provide inferior improvement in lower urinary tract symptoms (LUTS) when compared to transurethral resection of the prostate (TURP) and simple prostatectomy. Aquablation demonstrates similar improvement in LUTS while significantly minimizing ejaculatory dysfunction compared to TURP. Management of BPH must include patient counseling on the potential risks of sexual dysfunction associated with both medical and surgical therapies. Future research should be guided towards comparing minimally invasive surgical therapies to one another and collecting long-term data on the durability of these therapies on urinary and sexual function.
本综述旨在评估近期围绕良性前列腺增生（BPH）的新型药物和手术治疗对性健康和功能影响的文献。
近期评估接受Optilume、Rezum、Urolift、iTind和前列腺动脉栓塞治疗患者的随机对照试验报告称，性功能障碍发生的相关风险极小。然而，与经尿道前列腺切除术（TURP）和单纯前列腺切除术相比，这些治疗在改善下尿路症状（LUTS）方面效果较差。与TURP相比，水刀消融术在改善LUTS方面效果相似，同时显著减少射精功能障碍。BPH的管理必须包括就药物和手术治疗相关的性功能障碍潜在风险对患者进行咨询。未来的研究应致力于比较微创外科治疗方法，并收集这些治疗方法对泌尿和性功能长期疗效的长期数据。
